TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16291981

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg per day
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Lifestyle modification counseling alone
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Sibutramine plus lifestyle modification counseling (combined therapy)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Sibutramine plus brief lifestyle modification counseling
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Combined therapy with frequent food intake recording
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Combined therapy with infrequent food intake recording
Number of subjects: 224
Study: 12077767

Group type: COMPARATOR
Intervention: IL-1ra
Number of subjects: 34

Group type: COMPARATOR
Intervention: IL-6
Number of subjects: 34

Group type: COMPARATOR
Intervention: TNF-alpha
Number of subjects: 34
Study: 9801481

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 33

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 33
Study: 8749868

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (8 mmol over 5 min followed by 65 mmol over 24 h)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 78
Study: 2708970

Group type: EXPERIMENTAL
Intervention: Exposure and response prevention of bingeing (ERPB)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Exposure and response prevention of vomiting (ERPV)
Number of subjects: 11
Study: 732289

Group type: EXPERIMENTAL
Intervention: 16-hour training programs
Number of subjects: 55

Group type: COMPARATOR
Intervention: Other human services curricula
Number of subjects: 55
Study: 31053213

Group type: EXPERIMENTAL
Intervention: Sleep extension for 2 weeks (mean sleep duration 396 [25] minutes, extended by 60.1 [28.5] minutes)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sleep extension for 2 weeks
Number of subjects: 21
Study: 29103081

Group type: EXPERIMENTAL
Intervention: TAK-063
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 26499057

Group type: EXPERIMENTAL
Intervention: ACTIVATE™ computer program, used at home for 40 minutes per day, 6 days per week for 8 weeks.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Treatment as usual (Control group).
Number of subjects: 122
Study: 23803951

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505

Group type: EXPERIMENTAL
Intervention: Ivabradine (Holter substudy)
Number of subjects: 6505
Study: 21254911

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg once weekly
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination of RLX and ALN
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 135
Study: 19371824

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6556
Study: 17719326

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy Driver stents (ZES)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 343
Study: 15041932

Group type: EXPERIMENTAL
Intervention: ADP 2 microM
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ADP 5 microM
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ADP 10 microM
Number of subjects: 34
Study: 10773175

Group type: EXPERIMENTAL
Intervention: Active control groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved disease taxonomies and severity indices
Number of subjects: 0
Study: 9012582

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study: 8449578

Group type: EXPERIMENTAL
Intervention: 700 mg pivampicillin tablet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 700 mg pivampicillin tablet with food
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 700 mg pivampicillin tablet with antacid
Number of subjects: 14
Study: 3020162

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) at 10 mg/kg body weight at 8 h intervals for 7 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31376619

Group type: EXPERIMENTAL
Intervention: Insulin glulisine in Apidra®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin glargine in Lantus® and Toujeo®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 27412502

Group type: EXPERIMENTAL
Intervention: Short message service (SMS) intervention for drug consumption motivation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group with health providers and outreach workers monitoring
Number of subjects: 90
Study: 26281910

Group type: EXPERIMENTAL
Intervention: Fathers' intake of fruit
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Fathers' intake of vegetables
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Fathers' intake of sweet snacks
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Fathers' intake of savoury snacks
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Fathers' intake of take-away foods
Number of subjects: 317
Study: 23691825

Group type: EXPERIMENTAL
Intervention: Simulated hearing loss at three levels during Callsign Acquisition Test (CAT) stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent navigation task while performing CAT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Navigation task with no CAT
Number of subjects: 0
Study: 21534749

Group type: EXPERIMENTAL
Intervention: Intravenous low-dose magnesium sulphate (0.75 g/h after a loading dose of 4 g)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard intramuscular regimen (as advocated by Pritchard)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Intravenous low-dose magnesium sulphate
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard intramuscular regimen
Number of subjects: 144
Study: 19486260

Group type: EXPERIMENTAL
Intervention: Whole-fat dairy supplementation (3.5 servings/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-fat dairy supplementation (3.5 servings/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of whole-fat vs low-fat dairy
Number of subjects: 45
Study: 16438759

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2 g in 100 mL of saline solution)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (100 mL of saline)
Number of subjects: 100
Study: 12778857

Group type: EXPERIMENTAL
Intervention: Low-phosphorus diet
Number of subjects: 51

Group type: COMPARATOR
Intervention: Calcium carbonate 2.5 g/day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Calcium carbonate 5 g/day
Number of subjects: 51
Study: 10746617

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg tid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (tid)
Number of subjects: 30
Study: 8694170

Group type: EXPERIMENTAL
Intervention: Warmed propofol at 37 degrees C
Number of subjects: 101

Group type: COMPARATOR
Intervention: Room temperature propofol
Number of subjects: 101
Study: 1510454

Group type: EXPERIMENTAL
Intervention: 600 mg of rifampin twice daily on study days 6 and 7 (group A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 600 mg of rifampin once daily on days 4, 5, 6, and 7 (group B)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4-day regimen (group B)
Number of subjects: 14
Study: 6625963

Group type: EXPERIMENTAL
Intervention: Active dialysis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Inactive dialysis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham dialysis
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Active dialysis and Inactive dialysis
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Plasma from patients during dialysis
Number of subjects: 7
Study: 31910649

Group type: EXPERIMENTAL
Intervention: Routine CMR
Number of subjects: 500

Group type: COMPARATOR
Intervention: Selective CMR
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Specific HF causes from imaging
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Nonspecific HF causes from imaging
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Specific HF causes from clinical assessment
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Nonspecific HF causes from clinical assessment
Number of subjects: 500
Study: 30554783

Group type: EXPERIMENTAL
Intervention: 10 mg pegbelfermin once a day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 20 mg pegbelfermin once a week
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 28601693

Group type: EXPERIMENTAL
Intervention: Inverse reasoning training (n = 64)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Healthy sensory-based reasoning (n = 65)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control condition (n = 58)
Number of subjects: 187
Study: 27592038

Group type: EXPERIMENTAL
Intervention: Cervical physical therapy for 6 weeks (12 sessions)
Number of subjects: 38
Study: 24094133

Group type: EXPERIMENTAL
Intervention: Website trust cue factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived DTC website trust
Number of subjects: 0
Study: 23318238

Group type: EXPERIMENTAL
Intervention: Community-centred eco-bio-social intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Routine service area (control)
Number of subjects: 1200
Study: 20561917

Group type: EXPERIMENTAL
Intervention: Tazobactam/piperacillin (TAZ/PIPC) 5 g intravenously every 12 h
Number of subjects: 100

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IPM/CS) 1 g intravenously every 12 h
Number of subjects: 100
Study: 17605234

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) 30 g/d for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (received RS in late 4 weeks)
Number of subjects: 40
Study: 15618801

Group type: EXPERIMENTAL
Intervention: Continuous double epidural catheter technique with ropivacaine 0.3%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous intravenous morphine
Number of subjects: 30
Study: 11868800

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg daily for 5 days + 80 mg lovastatin
Number of subjects: 12

Group type: COMPARATOR
Intervention: 80 mg lovastatin alone
Number of subjects: 12
Study: 10594528

Group type: EXPERIMENTAL
Intervention: 5 microg DDAVP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 microg DDAVP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15 microg DDAVP
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study: 7491848

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 49
Study: 1639906

Group type: EXPERIMENTAL
Intervention: Automated high-performance liquid chromatographic method for rifampicin analysis
Number of subjects: 0
Study: 6093511

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1 g
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 1 g
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 0.5 g
Number of subjects: 8
Study: 31184022

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (Brudi PLUS) 350 mg, 3 times a day for 90 days
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (Brudi PLUS)
Number of subjects: 109
Study: 29475928

Group type: EXPERIMENTAL
Intervention: Thera tears (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Wet therapy (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tears Naturale free (Group C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups (Thera tears, Wet therapy, Tears Naturale free)
Number of subjects: 45
Study: 26350998

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 27
Study: 23235801

Group type: EXPERIMENTAL
Intervention: R-ACVBP (ACVBP plus rituximab)
Number of subjects: 223

Group type: COMPARATOR
Intervention: ACVBP (control group)
Number of subjects: 223
Study: 21787505

Group type: EXPERIMENTAL
Intervention: NaOCl/TBO/light group (0.1%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaOCl (0.66%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TBO/light groups (2.9%)
Number of subjects: 0
Study: 19131173

Group type: EXPERIMENTAL
Intervention: Olanzapine OST (10mg QD, 8 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Olanzapine ODT (10mg QD, 8 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study: 16459721

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 14672967

Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hypoxia (Hyp)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo control (Norm)
Number of subjects: 14
Study: 11782219

Group type: EXPERIMENTAL
Intervention: Myopic eyes with low IOP readings
Number of subjects: 32918

Group type: EXPERIMENTAL
Intervention: Increasing myopia
Number of subjects: 32918

Group type: EXPERIMENTAL
Intervention: Normal tension glaucoma
Number of subjects: 32918

Group type: EXPERIMENTAL
Intervention: Increasing IOP
Number of subjects: 32918
Study: 8935444

Group type: EXPERIMENTAL
Intervention: RU 486
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1563189

Group type: EXPERIMENTAL
Intervention: Antibiotic (14 days, n = 8)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (14 days, n = 4; 7 days, n = 1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bronchodilators and physiotherapy
Number of subjects: 13
Study: 4082879

Group type: EXPERIMENTAL
Intervention: Combined general anaesthesia and epidural analgesia with etidocaine 1.5% intraoperatively and bupivacaine 0.5% 5 ml/4 h for 24 h and morphine 4 mg/12 h for 72 h
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anaesthesia (low‐dose fentanyl) and systemic morphine for postoperative pain
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anaesthesia and low‐dose heparin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 100
Study: 30932181

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-β1a
Number of subjects: 0
Study: 30172759

Group type: EXPERIMENTAL
Intervention: FTD/TPI
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study: 26563287

Group type: EXPERIMENTAL
Intervention: Osteosarcopenic
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sarcopenic
Number of subjects: 68

Group type: COMPARATOR
Intervention: Osteopenic
Number of subjects: 68

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 68
Study: 25326007

Group type: EXPERIMENTAL
Intervention: Listening to the radio daily
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Receiving more services in ANC
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Receiving more delivery services
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Experiencing disrespect and abuse during delivery
Number of subjects: 855
Study: 22496085

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) 500 mg intravenous bolus immediately before PPCI followed by a 12-hour infusion (50 mg/kg of body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline bolus and infusion (placebo group)
Number of subjects: 60
Study: 20173088

Group type: EXPERIMENTAL
Intervention: Omnitrope lyophilisate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omnitrope liquid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Genotropin
Number of subjects: 24
Study: 17485956

Group type: EXPERIMENTAL
Intervention: Prophylactic parenteral antibiotics (carbapenems intravenously)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 10
Study: 16284583

Group type: EXPERIMENTAL
Intervention: 0.5% Marcaine (treatment group, n = 15)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal saline (control group, n = 22)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (Marcaine and control)
Number of subjects: 37
Study: 12235692

Group type: EXPERIMENTAL
Intervention: Investigated group (carbohydrate metabolism disturbances)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (normal OGTT)
Number of subjects: 80
Study: 9972757

Group type: EXPERIMENTAL
Intervention: 10 microg of sufentanil plus 2.5 mg of bupivacaine (Group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Half the dose of sufentanil and bupivacaine (Group B)
Number of subjects: 42
Study: 7751431

Group type: EXPERIMENTAL
Intervention: XR diltiazem 240 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: XR diltiazem 480 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: XR diltiazem (120-480 mg range)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: XR diltiazem
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 2112173

Group type: EXPERIMENTAL
Intervention: Mental imagery technique for practicing ORCPR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no mental imagery)
Number of subjects: 0
Study: 342300

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate 4 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate 8 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Codeine phosphate 60 mg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 30543732

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB + β-TCP
Number of subjects: 12

Group type: COMPARATOR
Intervention: β-TCP alone
Number of subjects: 12
Study: 28494898

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100
Study: 26116778

Group type: EXPERIMENTAL
Intervention: 10-minute audio-instructed mindfulness meditation
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10-minute rest condition with audio-description of mindfulness meditation
Number of subjects: 60
Study: 23369415

Group type: EXPERIMENTAL
Intervention: PBI plus booster brochures (PBI‐B)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: PBI
Number of subjects: 443

Group type: COMPARATOR
Intervention: Assessment only control group (CNT)
Number of subjects: 443
Study: 20921919

Group type: EXPERIMENTAL
Intervention: Group A (retested at 4 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group B (retested at 8 months)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 24
Study: 19221759

Group type: EXPERIMENTAL
Intervention: Unilateral renal embolization (URE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bilateral renal embolization (BRE)
Number of subjects: 16
Study: 17056241

Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Formoterol + Tiotropium
Number of subjects: 36
Study: 14739799

Group type: EXPERIMENTAL
Intervention: Surgical attire
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Protective gear
Number of subjects: 84

Group type: COMPARATOR
Intervention: Both conditions
Number of subjects: 84
Study: 9506205

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7923514

Group type: EXPERIMENTAL
Intervention: Lidocaine 4%, 10%, 20%, 30%, 50% with 5-minute iontophoresis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine 4%, 10%, 20%, 30%, 50% with 10-minute iontophoresis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine 50% with 5-minute iontophoresis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine 50% with 10-minute iontophoresis
Number of subjects: 20
Study: 3281031

Group type: EXPERIMENTAL
Intervention: 60 Gy plus carmustine (BCNU)
Number of subjects: 626

Group type: COMPARATOR
Intervention: 60 Gy alone
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: 60 Gy plus BCNU
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: 60 Gy plus 10‐Gy boost
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: 60 Gy plus semustine plus dacarbazine
Number of subjects: 626
Study: 29801741

Group type: EXPERIMENTAL
Intervention: 8-session group psychosocial intervention (ACHD-CARE)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 42
Study: 28441896

Group type: EXPERIMENTAL
Intervention: Fluoxetine (⩽80 mg/day) for 12 weeks
Number of subjects: 112
Study: 26654798

Group type: EXPERIMENTAL
Intervention: computer-training program to improve self-regulation abilities
Number of subjects: 226

Group type: COMPARATOR
Intervention: placebo control group
Number of subjects: 226
Study: 23849147

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive trial design
Number of subjects: 720

Group type: COMPARATOR
Intervention: Trial without adaptive randomization
Number of subjects: 720
Study: 20693276

Group type: EXPERIMENTAL
Intervention: Hyposmic/anosmic participants
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normosmic control participants
Number of subjects: 63
Study: 19043911

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15725285

Group type: EXPERIMENTAL
Intervention: Detergent
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Disinfectant
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Disinfectant/Detergent
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control area
Number of subjects: 15
Study: 12921248

Group type: EXPERIMENTAL
Intervention: Corticosteroid approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytotoxic therapies (chlorambucil, cyclophosphamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental therapies
Number of subjects: 0